GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Revenue

Innovative Pharmaceutical Biotech (HKSE:00399) Revenue : HK$7.66 Mil (TTM As of Sep. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech Revenue?

Innovative Pharmaceutical Biotech's revenue for the six months ended in Sep. 2023 was HK$3.73 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was HK$7.66 Mil. Innovative Pharmaceutical Biotech's Revenue per Share for the six months ended in Sep. 2023 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.01.

Warning Sign:

Innovative Pharmaceutical Biotech Ltd revenue per share has been in decline for the last 5 years.

During the past 3 years, the average Revenue per Share Growth Rate was -15.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Innovative Pharmaceutical Biotech's highest 3-Year average Revenue per Share Growth Rate was 122.00% per year. The lowest was -79.00% per year. And the median was -15.70% per year.


Innovative Pharmaceutical Biotech Revenue Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech Revenue Chart

Innovative Pharmaceutical Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.59 14.58 15.19 11.15 8.08

Innovative Pharmaceutical Biotech Semi-Annual Data
Dec13 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 4.51 4.14 3.94 3.73

Competitive Comparison of Innovative Pharmaceutical Biotech's Revenue

For the Household & Personal Products subindustry, Innovative Pharmaceutical Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative Pharmaceutical Biotech's Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Innovative Pharmaceutical Biotech's Revenue distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's Revenue falls into.



Innovative Pharmaceutical Biotech Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$7.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovative Pharmaceutical Biotech  (HKSE:00399) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Innovative Pharmaceutical Biotech Revenue Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Traded in Other Exchanges
N/A
Address
168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.
Executives
Mao Yumin 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Chau Yiu Ting 2101 Beneficial owner
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines